Ophthalmic Viscosurgical Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Ophthalmic Viscosurgical Devices Market Trends and Insights

Demographic Expansion of the Cataract-Prone Elderly Cohort

Disability-adjusted life years lost to cataract rose from 6.68 million in 2019 to 7.1 million in 2021 and could exceed 7.5 million by 2025 if incidence trends hold^{[1]Thomas R. et al., “Global Burden of Disease Cataract Update,” nature.com}. A 2024 meta-analysis logged 17 million people blind and 83.5 million experiencing moderate-to-severe visual impairment from cataract in 2020. Hospitals in high-income countries now face six-week median waitlists for extraction slots, directly inflating baseline use of viscoelastic syringes. Every additional year of life expectancy raises the surgical funnel, ensuring that the ophthalmic viscosurgical devices market keeps outpacing the broader ophthalmology consumables sector. Forward bookings released in early 2025 underscore unmet demand, implying stronger device pull-through even when per-procedure dosing remains constant.

Escalating Incidence of Diabetes-Linked Ocular Complications

Adults with diabetes develop cataract earlier and more aggressively than non-diabetic peers, pulling forward first-surgery age and lengthening lifetime exposure to viscoelastics. Routine early screening raises intervention rates that spill over into glaucoma and vitrectomy indications. Manufacturers now emphasize formulas that temper postoperative intraocular pressure spikes, positioning such attributes as clinical differentiators. Surgeons treating younger diabetic cohorts favor viscoadaptives that preserve endothelial integrity, reinforcing premium-tier demand. The ophthalmic viscosurgical devices market therefore benefits from a double-lift of larger patient cohorts and higher-value product mix.

Technological Evolution in Phaco, Femto and MIGS Platforms

Femtosecond laser-assisted cataract surgery produces micro-bubble turbulence that threatens corneal endothelium without high-molecular-weight buffering. As micro-incision tips enter mainstream use, surgeons demand viscoadaptive blends that hold chamber depth yet evacuate debris swiftly. Rapid growth in MIGS procedures intensifies calls for ultra-clear, low-particulate viscoelastics that do not obscure gonioscopic views. These platform advances raise performance expectations and solidify the ophthalmic viscosurgical devices market as a growth outlier among single-use surgical supplies.

Growing Surgical Capacity via ASCs and National Blindness-Prevention Programs

ASCs now conduct nearly one in five Medicare-funded cataract operations in the United States. Lower overhead speeds payback on premium gear, encouraging uptake of high-performance ophthalmic viscosurgical agents that shorten chair time. Across Asia, government-backed cataract campaigns equip outreach units with compact kits that bundle pre-filled viscoelastic syringes, generating bulk orders during high-volume surgical days. This temporal clustering of demand helps manufacturers plan production runs and smooth inventory cycles for the ophthalmic viscosurgical devices market.

Price Sensitivity and Reimbursement Caps on Premium OVD Grades

ASC payments are tethered to the hospital outpatient schedule, bundling viscoelastic costs into wider cataract reimbursement packages. When payment ceilings squeeze margins, procurement teams pivot toward mid-tier formulations or negotiate bulk discounts. European hospitals operating under value-based budgets demand peer-reviewed endothelial cell-loss data before approving costlier upgrades, favoring companies that fund robust clinical-support programs. This reimbursement compression moderates premium-mix expansion within the ophthalmic viscosurgical devices market without derailing overall volume growth.

Availability of Low-OVD or OVD-Free Surgical Techniques

New fluidics systems stabilize the anterior chamber with balanced salt solution, reducing viscoelastic volume per case. Pilot audits show tangible cutbacks, yet surgeons still rely on OVDs for capsulorhexis and lens implantation phases. Immediate sequential bilateral cataract surgery promises per-patient efficiencies but usually mandates separate single-use packs for risk control, partially offsetting consumption declines. The net effect is a gradual, not precipitous, tempering of demand within the ophthalmic viscosurgical devices market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type: Dispersive Agents Dominate, Viscoadaptives Accelerate

Dispersive agents accounted for the largest 37.33% share of the ophthalmic viscosurgical devices market size in 2025, benefiting from their ability to coat delicate tissue during nucleus disassembly. Surgeons manage complex cataract presentations—pseudoexfoliation, shallow chambers, post-LASIK cases—by alternating dispersive and cohesive OVDs within a single procedure, lifting per-case volume. Innovators now embed anti-oxidant additives into dispersive formulations, defending price points even in cost-sensitive tenders.

Viscoadaptive blends are expanding fastest at a 7.59%CAGR to 2031, propelled by premium intraocular lens (IOL) cases that demand superior endothelial protection. These agents behave cohesively under low shear and disperse under high flow, maintaining chamber stability during phacoemulsification or femtosecond fragmentation. Manufacturers tie viscoadaptive syringes to injector systems, locking in surgeon loyalty and deepening penetration of the ophthalmic viscosurgical devices market.

By Source: Biological Hyaluronic Acid Leads, Fermentation Grades Gain Ground

Bacteria-derived hyaluronic acid secured a 39.02% slice of the ophthalmic viscosurgical devices market share in 2025, prized for consistent chain length and low immunogenicity. Hospitals align these products with sustainability scorecards that favor animal-free sourcing. Supply reliability further cements the segment’s leadership.

Semi-synthetic/fermentation grades are slated for an 8.74%CAGR through 2031. Fermentation allows rapid scale-up and precise molecular-weight control, enabling custom blends for combined cataract–glaucoma cases. Procurement teams appreciate insulation from livestock disease shocks, increasing the strategic appeal of fermentation routes within the ophthalmic viscosurgical devices market. Animal-derived sources retain a foothold on price but are ceding ground as regulators endorse animal-protein reduction.

By Application: Cataract Still the Workhorse, Glaucoma Emerging

Cataract surgery generated 50.17% of the ophthalmic viscosurgical devices market size in 2025. Procedure volumes in the United States top 4 million annually and are heading toward 6 million by 2030. Every cataract case consumes at least one syringe, anchoring baseline demand. Hospitals now schedule extended evening lists to cut waiting times, an operational change that further lifts syringe uptake.

Glaucoma procedures contribute a smaller absolute share but show the strongest 6.47%CAGR through 2031. Micro-invasive glaucoma surgery relies on precise viscoelastic delivery to protect angle structures, spurring formulary committees to stock specialized rheologies. Diagnostic screening programs detect disease earlier, expanding the addressable pool and nudging the ophthalmic viscosurgical devices market toward higher procedural diversity.

By End User: Hospitals Anchor Demand, ASCs Accelerate

Hospitals held 59.74% of ophthalmic viscosurgical devices market share in 2025 as they manage complex cases and pioneer premium viscoadaptive adoption. Central purchasing across multi-state networks safeguards supply continuity, reinforcing incumbent brands. Teaching hospitals also run comparative trials that shape regional formularies, indirectly steering market preferences.

ASCs record the fastest 8.06%CAGR to 2031, buoyed by a 15.41% year-on-year jump in Medicare payments in 2023. Their efficiency focus tilts product selection toward single-use packs that cut turnover time. Specialty clinics maintain a steady presence by serving premium or complex cohorts, and nascent office-based suites could spawn a micro-tier of compact viscoelastic syringes, adding nuance to the ophthalmic viscosurgical devices market.

Geography Analysis

North America represented 37.58% of the global ophthalmic viscosurgical devices market size in 2025, underpinned by robust reimbursement and dense ophthalmologist distribution. Medicare confirms cataract extraction as the top surgical episode in ASCs at roughly 19% of volume. Nearly 27.8% of U.S. adults aged 71+ report visual impairment, reinforcing surgical load. Bundled purchase agreements that link viscoelastic with phaco tips and IOL injectors are gaining traction, cementing supplier lock-in.

Asia-Pacific posts the highest 7.68%CAGR to 2031. Expanding health insurance in China and India drives cataract penetration, while provincial facilities transition to femtosecond platforms needing advanced viscoelastics. Surveys from Southwest China reveal a rising share of cataract patients with prior refractive surgery or high myopia. As reimbursement begins to acknowledge premium IOLs, dual-action viscoadaptives capture surgeon preference, lifting regional mix and directing incremental revenue into the ophthalmic viscosurgical devices market.

Europe sustains a sizable base yet faces tighter value-based procurement. Hospitals demand head-to-head endothelial cell-loss data before approving premium upgrades, favoring firms with strong clinical-evidence budgets. Regional societies advocate electronic instructions for use, aiming to cut intraocular lens packaging emissions by 67%. Early compliance with eco-qualified packaging may enhance tender scores and preserve share in the ophthalmic viscosurgical devices market.

Regulatory Landscape

Ophthalmic viscosurgical devices (OVDs) align with ISO 15798:2022, which defines safety, performance, evaluation, and labeling requirements and is commonly used by manufacturers to structure technical documentation and testing. In the European Union, OVDs are governed under Regulation (EU) 2017/745 (MDR), where compliance with the General Safety and Performance Requirements and defensible clinical evidence influence access and ongoing lifecycle updates.

In the United States, OVDs are regulated by the FDA and commonly managed through the Premarket Approval (PMA) framework, so manufacturing, supplier, and site changes require PMA supplements. Recent FDA activity highlights this lifecycle-control intensity: in February 2026 Alcon received a PMA supplement approval (P840064/S089) for a new 0.75 mL fill volume for Viscoat produced at the LifeCore Biomedical facility, and in December 2025 and December 2024 Johnson & Johnson Surgical Vision obtained PMA supplement approvals (P810031/S081 and P810031/S076) covering an alternative supplier for a delivery-system component and an additional storage facility for Healon products.

Market Opportunities and Future Outlook

Lifecycle-management and SKU optimization create near-term whitespace as surgical centers balance inventory constraints with rising throughput. FDA approvals for manufacturing and configuration changes show where suppliers are reducing friction in hospital and ASC workflows, including Alcon's February 2026 PMA supplement approval enabling a new 0.75 mL fill volume for Viscoat at LifeCore Biomedical. That supports procedure- and setting-specific pack sizes, including single-use, full-procedure kits, which can improve turnover while staying aligned with reimbursement-driven cost controls.

Portfolio and channel expansion is another opportunity vector, especially where cataract ecosystems are being broadened through commercial rights and bundled offerings. Rayner's March 2026 announcement to acquire U.S. distribution rights for Anikavisc indicates that access to established OVD products is being treated as a strategic lever alongside IOLs and cataract platforms, strengthening cross-sell pathways with surgeon accounts. At the same time, FDA-recognized supply-chain flexibility, such as Johnson & Johnson Surgical Vision's December 2025 PMA supplement approval for an alternative supplier for a Healon delivery component, underscores demand for resilient sourcing and validated process options that reduce disruption risk for high-volume cataract and MIGS schedules.